324 related articles for article (PubMed ID: 37395750)
21. Covalent targeting of acquired cysteines in cancer.
Visscher M; Arkin MR; Dansen TB
Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
[TBL] [Abstract][Full Text] [Related]
22. Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile.
Zhang Z; Morstein J; Ecker AK; Guiley KZ; Shokat KM
J Am Chem Soc; 2022 Sep; 144(35):15916-15921. PubMed ID: 36001446
[No Abstract] [Full Text] [Related]
23. Targeting K-Ras Mutations Show Promise Towards Ending Ras's "Undruggable" Era.
Adams PD; Muhoza D
Protein Pept Lett; 2022; 29(12):1007-1015. PubMed ID: 36200189
[TBL] [Abstract][Full Text] [Related]
24. A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).
Li N; Liu CF; Zhang W; Rao GW
Curr Med Chem; 2023 Nov; ():. PubMed ID: 37936461
[TBL] [Abstract][Full Text] [Related]
25. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
26. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
[TBL] [Abstract][Full Text] [Related]
27. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
28. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
Kumar SU; Priya Doss CG
Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
[TBL] [Abstract][Full Text] [Related]
29. KRAS G12C fragment screening renders new binding pockets.
Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
32. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.
Poorebrahim M; Abazari MF; Moradi L; Shahbazi B; Mahmoudi R; Kalhor H; Askari H; Teimoori-Toolabi L
PLoS Comput Biol; 2022 Apr; 18(4):e1009962. PubMed ID: 35472201
[TBL] [Abstract][Full Text] [Related]
33. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
[TBL] [Abstract][Full Text] [Related]
34. Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics.
Yoo DY; Hauser AD; Joy ST; Bar-Sagi D; Arora PS
ACS Chem Biol; 2020 Jun; 15(6):1604-1612. PubMed ID: 32378881
[TBL] [Abstract][Full Text] [Related]
35. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
36. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
Stalnecker CA; Der CJ
Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
[TBL] [Abstract][Full Text] [Related]
37. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
38. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
40. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
Hyun S; Shin D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
